Short answer
aTYR PHARMA INC (ATYR) filed an 8-K current report with the SEC on August 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Quarterly financial results cover the period ended June 30, 2026.
aTYR PHARMA INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Quarterly financial results cover the period ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the detailed results
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 revenue-free biotech reported net loss $10.3M, or $0.11 per share, versus $19.5M, or $0.22, in Q2 2025
- Cash and investments fell to $58.9M from $80.9M at December 31, 2025, funding operations into late 2028 under current plans
- Planned pulmonary sarcoidosis Phase 3 requires additional capital, creating future financing and dilution risk
- Approximately 60% workforce reduction targets $13M in annualized operating-expense savings beginning Q4 2026
- FDA feedback expected by end-August 2026; SSc-ILD Phase 2 enrollment complete with topline results expected Q1 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other aTYR PHARMA INC 8-K filings
Get the next ATYR 8-K as it lands
Follow ATYR for push alerts, or ask the research agent what this filing means.